Search Results - "Dobber JA"

Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.

Authors: Kater AP Kersting S Dubois JM et al.

Source: The Lancet. Haematology [Lancet Haematol] 2025 Dec; Vol. 12 (12), pp. e935-e945.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Authors: Niemann CU Dubois J Nasserinejad K et al.

Source: Blood advances [Blood Adv] 2025 Aug 12; Vol. 9 (15), pp. 3665-3675.

Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.

Authors: Hengeveld PJ Schilperoord-Vermeulen J van der Klift MY et al.

Source: Blood cancer journal [Blood Cancer J] 2023 Jul 04; Vol. 13 (1), pp. 102. Date of Electronic Publication: 2023 Jul 04.

Publication Type: Letter; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.

Authors: Amaador K Vos JMI Pals ST et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 May; Vol. 63 (5), pp. 1070-1079. Date of Electronic Publication: 2021 Dec 27.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.

Authors: Svanberg R Ostrowski SR Nasserinejad K et al.

Source: Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (14), pp. 3422-3431. Date of Electronic Publication: 2020 Aug 31.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.

Authors: van der Straten L Stege CAM Kersting S et al.

Source: Blood [Blood] 2023 Sep 28; Vol. 142 (13), pp. 1131-1142.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Multicenter study to evaluate a new enumeration method for hematopoietic stem cell collection management.

Authors: Grommé M Russcher H Braakman E et al.

Source: Transfusion [Transfusion] 2017 Aug; Vol. 57 (8), pp. 1949-1955. Date of Electronic Publication: 2017 Jun 26.

Publication Type: Evaluation Study; Journal Article; Multicenter Study

Journal Info: Publisher: American Association Of Blood Banks Country of Publication: United States NLM ID: 0417360 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-2995 (Electronic) Linking ISSN: 00411132 NLM ISO Abbreviation: Transfusion Subsets: MEDLINE

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Authors: Kater AP Levin MD Dubois J et al.

Source: The Lancet. Oncology [Lancet Oncol] 2022 Jun; Vol. 23 (6), pp. 818-828.

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Authors: Kersting S Dubois J Nasserinejad K et al.

Corporate Authors: Kersting S Dubois J Nasserinejad K et al.

Source: The Lancet. Haematology [Lancet Haematol] 2022 Mar; Vol. 9 (3), pp. e190-e199.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Authors: Niemann CU Levin MD Dubois J et al.

Source: Blood [Blood] 2021 Feb 25; Vol. 137 (8), pp. 1117-1120.

Publication Type: Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.

Authors: Saberi Hosnijeh F van der Straten L Kater AP et al.

Source: Experimental hematology [Exp Hematol] 2020 Sep; Vol. 89, pp. 55-60.e6. Date of Electronic Publication: 2020 Aug 08.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article

Journal Info: Publisher: Elsevier Science Inc Country of Publication: Netherlands NLM ID: 0402313 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2399 (Electronic) Linking ISSN: 0301472X NLM ISO Abbreviation: Exp Hematol Subsets: MEDLINE

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Authors: de Weerdt I Hofland T de Boer R et al.

Source: Blood advances [Blood Adv] 2019 Sep 10; Vol. 3 (17), pp. 2642-2652.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Authors: Kater AP van Oers MHJ van Norden Y et al.

Corporate Authors: Kater AP van Oers MHJ van Norden Y et al.

Source: Haematologica [Haematologica] 2019 Jan; Vol. 104 (1), pp. 147-154. Date of Electronic Publication: 2018 Aug 16.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study

Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.

Authors: Kater AP Kersting S van Norden Y et al.

Corporate Authors: Kater AP Kersting S van Norden Y et al.

Source: Blood advances [Blood Adv] 2018 Dec 26; Vol. 2 (24), pp. 3566-3571.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE